Larynx Cancer Market Size, Share & Growth Analysis Report - Forecast Trends and Outlook (2025-2034)

The larynx cancer market was valued at USD 2.40 Billion in 2024, driven by the increased clinical research and trials across the 8 major markets. The market is expected to grow at a CAGR of 2.40% during the forecast period of 2025-2034, with the values likely to reach USD 3.04 Billion by 2034.

Larynx Cancer Market Overview

Larynx cancer (also known as laryngeal cancer or throat cancer) refers to a cancerous growth that occurs in the larynx (voice box). This cancer originates from the epithelium of the larynx and is considered a squamous-cell carcinoma. The market is driven by the increasing burden of larynx cancer due to factors such as tobacco use, alcohol consumption, and the rising incidence of human papillomavirus (HPV). The market also benefits from the advancements in diagnostic imaging technologies, such as CT scans, MRI, and PET scans, which allow early detection of the cancer required for successful treatment of the disease. Additionally, increased government and non-governmental initiatives aimed at promoting awareness about head and neck cancers and the risks associated with smoking and alcohol use are anticipated to impact the market dynamics positively.

Larynx Cancer Market Growth Drivers

Increasing Prevalence of Larynx Cancer Impacts Market Growth

Larynx cancer poses a serious global health concern, comprising one-third of the head and neck cancers. In the United Kingdom, nearly 2,400 new larynx cancer cases are diagnosed annually, with a majority of the patients in advanced stages of the disease, failing to survive beyond three years. On the other hand, in the United States, the American Cancer Society has estimated around 12,650 new cases of larynx cancer in 2024, with approximately 3,880 individuals projected to die from this cancer. The substantial burden of larynx cancer is expected to drive the demand for effective treatments, thereby, contributing to market growth.

Larynx Cancer Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Strategic Collaborations to Affect the Market Landscape Significantly

In January 2024, American biotech Inovio Pharmaceuticals formed a clinical collaboration and supply agreement with Coherus BioSciences, Inc., a commercial-stage biopharmaceutical company specializing in the development of novel immunotherapies for cancer, with an aim to assess the new combination therapy INO-3112 and LOQTORZI for the treatment of HPV16/18 positive throat cancer. Such strategic partnerships are likely to advance clinical research for cancer treatments and also influence market growth.

Robust Research Initiatives Poised to Augment Larynx Cancer Market Demand

In December 2023, a study published in the Journal of Laryngology & Otology revealed the development of artificial intelligence-powered software with the capability to analyze medical imaging from CT scans. This tool can predict the survival of patients with advanced laryngeal cancer and is expected to guide personalized treatment for better clinical outcomes. Such robust research initiatives are projected to support market growth in the coming years.

Increasing Use of Immunotherapy and Targeted Therapies to Elevate the Larynx Cancer Market Value

One of the major market trends is the increased use of immunotherapies such as immune checkpoint inhibitors for the treatment of advanced or recurrent laryngeal cancer and for patients who are responding well to conventional treatments like surgery and chemotherapy. In addition, the growing adoption of targeted therapies that are designed to affect molecular alterations in cancer cells, are anticipated to elevate the market value in the forecast period.

Rising Cancer Awareness Campaigns to Boost Larynx Cancer Market Size

The market is witnessing increased efforts by the government and non-governmental organizations towards promoting awareness of head and neck cancers including larynx cancers and the dangers of smoking and alcohol abuse among the general public. Such awareness campaigns are facilitating early detection and increased treatment rates, which is likely to boost the market size.

Larynx Cancer Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type:

• Biologics
• Small Molecules

Market Breakup by Treatment Type:

• Chemotherapy
• Immunotherapy
• Targeted Drug Therapy
• Surgery
• Others

Market Breakup by Route of Administration:

• Oral
• Parenteral
• Others

Market Breakup by End User:

• Hospitals
• Clinics
• Diagnostic Centers
• Research Laboratories
• Others

Market Breakup by Region:

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Larynx Cancer Market Share

Market Segmentation Based on Type is Anticipated to Witness Substantial Growth

Based on the type of larynx cancer, the market is segmented into biologics and small molecules. The biologics segment is generating significant demand in the market as they offer more targeted approaches, resulting in fewer side effects compared to traditional chemotherapy and other conventional cancer treatments. These large-molecule therapies including immunotherapy drugs like immune checkpoint inhibitors are showing potential in the treatment of advanced or recurrent laryngeal cancers by boosting the ability of the body’s immune system to fight cancer cells.

Larynx Cancer Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a high market value. It can be attributed to the substantial demand for advanced therapies such as immunotherapy and precision medicine. The robust clinical trial activity in the country, with many of them being conducted in premium cancer centers, not only facilitates early access to novel therapies for patients but also contributes to the growth of the market. Moreover, the growing interest in personalized medicine and the rising preference for minimally invasive surgeries are poised to aid the market expansion in the region.

Leading Players in the Larynx Cancer Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AstraZeneca

Headquartered in Cambridgeshire, the United Kingdom, AstraZeneca, a science-led biopharmaceutical firm, is one of the major players in the market and is known for its strong focus on developing innovative treatments for various cancers including larynx cancer. The company's drug candidate Rilvegostomig (AZD-2936) is undergoing clinical development and is currently being assessed in a Phase II clinical trial for laryngeal cancer.

Pfizer Inc

Pharmaceutical giant Pfizer has a prominent presence in the market and boasts a robust pipeline of oncology products including biologics and immune-oncology therapies that have the potential to treat a wide array of cancers. The company is actively engaged in the development of new cancer drugs and is heavily investing in clinical trials.

AbbVie Inc

Headquartered in North Chicago, Illinois, AbbVie is a leading research-based biopharmaceutical company that is actively engaged in oncology research. The company is developing investigational therapies that may eventually be used for laryngeal cancer. For instance, AbbVie’s drug candidate ABBV-368 is undergoing clinical development for the treatment of solid tumors including laryngeal cancer and head and neck squamous cell carcinoma.

Lupin

Lupin Limited, a leading global pharmaceutical company based in India, specializes in the development of generic cancer treatments for different cancer types. The company’s oncology pipeline includes several promising cancer drugs that are undergoing clinical development.

Other key players in the market include Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, GSK plc, F. Hoffmann-La Roche Ltd, and Novartis AG.

Key Questions Answered in the Larynx Cancer Market Report

• What was the larynx cancer market value in 2024?
• What is the larynx cancer market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on the type of larynx cancer?
• What is the market breakup based on treatment type?
• What is the market breakup by the route of administration?
• Who are the major end users in the market?
• What are the major factors aiding the larynx cancer market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do the prevalence and incidence of larynx cancer affect the market landscape?
• What are the major larynx cancer market trends?
• How does the rise in the elderly population impact the market size?
• Which type of larynx cancer will dominate the market share?
• Which treatment type is expected to have a high market value in the coming years?
• Which route of administration will experience the highest demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the larynx cancer market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

More Insights On

Bladder Cancer Market

Advanced Ovarian Cancer Market

Head and Neck Cancer Market

Colorectal Cancer Market

Metastatic Prostate Cancer Market

Esophageal Cancer Market

Pancreatic Cancer Market

Gastric Cancer Market

Ovarian Cancer Market

This product will be delivered within 3-5 business days.